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2.2) 5-(Dimethyl-tert-butylsiloxy)-1,3-bis(di-tert-butylphosphite)benzene (p-TBDMSO-PCP-H).
A suspension of NaH (0.466 g, 19.4 mmol) in THF (44.0 mL) was slowly added via syringe to a solution of 5-(Dimethyl-tert-butylsiloxy)resorcinol (2.00 g, 8.8 mmol) in THF (130 mL). The mixture was heated to reflux for 1 h, a solution of di-tert-butylchlorophophine (3.33 g, 18.4 mmol) in THF (44.0 mL) was then added via syringe, and the mixture was refluxed for additional 1 h. After evaporation of the solvent in vacuum, the residue was extracted with toluene and filtered through a pad of Celite. After removal of toluene under vacuum, the flask was heated to 80 ºC for 2 h in vacuum to remove residual amount of di-tert- 
4) Synthesis of 4.
In 
5) Synthesis of 5.
In a typical procedure, 4 (160 mg, 44 mol based on a loading of 0.8 iridium complexes and NU-1000 as reference (top spectrum, red). of disorder is present in the structure, which was modeled using global bond restraints (RIGU) and distance constraints (DFIX and SADI). 
